In a report released Thursday the University of California, San Diego, was ranked among the top universities in the world for its prowess in developing and translating biotechnology into medical treatments, drugs and other commercial applications, according to university officials.
The 300-page study, released Thursday by the Milken Institute, an independent economic think tank, examines and ranks universities worldwide on several key factors that measure biotechnology development and transfer success, including published research, patents issued and commercial outcomes.
“We are very pleased to be recognized in this major study,” said Marye Anne Fox, UCSD chancellor. “UC San Diego has always taken its role as an economic engine for the region very seriously. Our ability to effectively transfer knowledge to the marketplace can be traced to both our longstanding commitment to entrepreneurship and innovation and university-industry partnerships. Our technology transfer office has played a significant role in this success, which has resulted in major economic, commercial, and healthcare benefits to the San Diego region and California.”
In addition to the rankings on publications and patent activity, where UC San Diego ranked sixth and eighth, respectively, the UC system overall was ranked second after MIT on technology transfer commercialization, which included startups, the number of new spin-off companies and patents issued.
UC San Diego was also singled out for its “exemplary performance” within the subfield of cell and developmental biology, where it received a 67 percent higher citation rate than the university average in the sample, according to officials.